Targeted Oncology - Immunotherapy, Biomarkers, and Cancer …
WEBSep 7, 2013 · In an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.
Adjuvant T-DM1 Continues to Outperform Trastuzumab in HER2 …
WEBDec 8, 2023 · After 8.4 years follow-up, T-DM1 (ado-trastuzumab emtansine; Kadcycla) led to improved overall survival (OS) and invasive disease-free survival (iDFS) over trastuzumab (Herceptin) in patients with HER2-positive early breast cancer that had residual invasive disease after neoadjuvant therapy, according to findings from the KATHERINE trial that were presented at the 2023 San Antonio Breast ...
Managing Chemotherapy Toxicities for Improved Patient Outcomes
WEBMar 29, 2021 · In a large majority of patients, even when treating with chemotherapy that is highly emetogenic, nausea and vomiting can be prevented. Options include 5-HT3 receptor antagonists (such as ondansetron), NK-1 receptor antagonists (such as aprepitant), glucocorticoids (such as dexamethasone), and olanzapine, a …
Treatment Strategies to Optimize Outcomes With Brentuximab …
WEBMay 19, 2015 · Ellen Neylon, RN. Columbia University Center. for Lymphoid Malignancies. New York, New York. Abstract. Background: Brentuximab vedotin is an antibody-drug conjugate that targets CD30-expressing cells and has demonstrated single-agent clinical efficacy in pivotal phase II trials in relapsed or refractory Hodgkin lymphoma after autologous stem cell transplant and in relapsed or refractory ...
FDA ODAC Votes Yes on Imetelstat for Patients with MDS
WEBMar 14, 2024 · The FDA’s Oncologic Drug Advisory Committee (ODAC) has voted that the benefits of imetelstat outweigh the risks for patients with lower-risk myelodysplastic syndromes (MDS) with anemia who are transfusion-dependent and ineligible for erythropoiesis stimulating agents (ESA). Findings from the IMerge/MDS3001 study (NCT02598661) were presented ...
Early-Stage NSCLC DFS Improved with Adjuvant Atezolizumab
WEBMay 19, 2021 · The 2-year DFS rate was 70.2% with atezolizumab vs 61.6% with best supportive care. The 3-year DFS rates were 55.7% and 49.4%, respectively. “Though surgery can cure some patients with early-stage lung cancer, disease recurrence is still very common. Until this trial, the only treatment that was …
FDA Lifts Partial Clinical Hold on Study of Odronextamab in FL and …
WEBMay 17, 2021 · Regeneron is resuming enrollment of patients with follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) in monotherapy trial of odronextamab (formally REGN19179) after the FDA lifted the partial clinical hold placed on the agent in December 2020, according to a press release by the company. 1 Monotherapy trials of odronextamab, a CD20xCD2 bispecific antibody, for patients with FL ...
FDA Approves Non-Alcohol Formulation of Docetaxel for Multiple …
WEBDec 29, 2015 · The FDA has approved a new treatment consisting of a non-alcohol formulation of docetaxel (Docetaxel Injection) in patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer. According to a statement from the manufacturer Teikoku Pharma, the formulation does not …
Predictors of Recurrence in Ovarian Cancer - Targeted Oncology
WEBApr 27, 2021 · Chirag Shah, MD, MPH: This is a fairly characteristic patient that we might see in my practice [Swedish Cancer Institute].The average age of incidence of most nongermline BRCA-mutated ovarian cancers is 61 years of age, so patients often present in the postmenopausal setting with fairly nonspecific symptoms.Thankfully, because of a number of advances that we are going to have the opportunity ...
NCCN Updates Breast Cancer Guidelines to Include Goserelin
WEBIn the January 25, 2024, update to Version 1.2024 of the NCCN invasive breast cancer guidelines, under principles for adjuvant endocrine therapy, the gonadotropin releasing hormone agonist goserelin is specified as a means for ovarian function suppression.2 It is administered subcutaneously at a dose of 3.6 mg every 4 weeks or 10.8 mg every 12 ...
Skip to content